Contact Us
Drug Search Results
More Filters [+]

Pegaptanib

Alternative Names: pegaptanib, macugen
Latest Update: 2024-09-04
Latest Update Note: News Article

Product Description

Pegaptanib, an anti-VEGF therapy, is the first agent to be used in clinical trials for AMD and the first aptamer used in clinical trials. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426796/)

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous,Ocular

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Colombia | European Medicines Agency | Germany | Greece | Hungary | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | New Zealand | Pakistan | Peru | Portugal | Romania | Slovenia | Spain | Sweden | Taiwan | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pegaptanib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/04/2024

News Article

 iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs

08/03/2023

News Article

 ImmunityBio Names Enrique Diloné as Chief Technology Officer

07/12/2023

News Article

 Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

03/06/2023

News Article

 EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions